• Home
  • Our Pipeline
  • About Us
  • Science
    • Active Immunotherapies
    • GlyMab®
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

H126: solid iSCIB1+ data underpins planned progress

by alex | Jan 29, 2026 | Immunobody, iSCIB1+, Moditope, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

FDA clears global Phase III trial for iSCIB1+

by alex | Jan 26, 2026 | Immunobody, iSCIB1+, Moditope, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

SCOPE Data Update: 11 December 2025

by alex | Dec 12, 2025 | Immunobody, Investor Presentations, iSCIB1+, SCIB1

European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 10-12 December 2025 in London

by chantal | Dec 10, 2025 | iSCIB1+, SCIB1, Vaccine, Vaccines

Kate Young, Samantha Paston, Heather Shaw, Pippa Corrie, Sarah Danson, Miranda Payne, Poulam Patel, Ioannis Karydis, Satish Kumar, Clare Barlow, Rebecca Lee, Martin Highley, Kellati Prasad, Georgia Goodhew, Gaëlle Cane, Joseph Chadwick, Sabaria Shah, Nermeen Varawalla...

Latest SCOPE data confirm durable improvement

by alex | Dec 9, 2025 | Immunobody, iSCIB1+, Moditope, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Abundant development opportunities in immuno-oncology

by chantal | Nov 17, 2025 | Immunobody, iSCIB1+, Moditope, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries

Recent Posts

  • Scancell announces CFO Transition
  • Edison Report – Redesigning immunity: The next frontier in immuno-oncology
  • Scancell Financial Year 2026 Interim Results
  • H126: solid iSCIB1+ data underpins planned progress
  • Interim Results and Business Update

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy